Dave brings with him more than 20 years of broad international operations and commercial experience in the CRO and CDMO sectors. Most recently, he was the CEO of Arranta Bio, a leading biologics CDMO specializing in mRNA, plasmid DNA, and microbiome live biotherapeutics, and Vibalogics, which focused on viral-based therapies and vaccines. Dave was a key member of the leadership team that started Arranta Bio in 2019, building out the organization and two advanced biologics development and GMP manufacturing facilities, culminating in the business being successfully acquired by Recipharm in 2022.
Prior to Arranta Bio, Dave was the Senior Vice President and Head of AMRI’s drug product business unit, where he had P&L responsibility for sales and operations. During his tenure, he led the division through a period of significant growth and capacity expansion. Prior to leading this division, Dave held senior leadership roles at AMRI, including as Vice President, Sales & Marketing, and General Manager of a sterile dosage form development and GMP manufacturing facility. In addition to Dave’s success at Arranta Bio, he held roles of increasing responsibility at Aptuit, including a long-term international assignment in Italy, where he led operational excellence and capacity planning for an R&D and clinical GMP facility with over 400 employees. He started his career at Inveresk and Charles River Laboratories.
Dave earned an undergraduate degree in business and an MBA in strategy, finance, and marketing from the University of Edinburgh.